Annals of the New York Academy of Sciences Nonalcoholic Fatty Liver Disease: an Emerging Threat to Obese and Diabetic Individuals
暂无分享,去创建一个
[1] Greger Lindberg,et al. Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.
[2] F. Pattou,et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.
[3] Roberto Pastor-Barriuso,et al. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.
[4] O. Cummings,et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network , 2011, Hepatology International.
[5] J. Barkin. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis , 2007 .
[6] P. Gill,et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. , 2013, Journal of hepatology.
[7] B. Neuschwander‐Tetri,et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.
[8] R. Torella,et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[9] K. Tanikawa,et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.
[10] M. Orešič,et al. Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver , 2009, Diabetes.
[11] L. Sechi,et al. Oxidative stress is activated by free fatty acids in cultured human hepatocytes. , 2011, Metabolic syndrome and related disorders.
[12] Å. Lernmark,et al. Hepatic steatosis in type 1 diabetes. , 2011, The review of diabetic studies : RDS.
[13] S. Harrison,et al. Nonalcoholic Fatty Liver Disease Presenting With an Isolated Elevated Alkaline Phosphatase , 2006, Journal of clinical gastroenterology.
[14] Jonathan C. Cohen,et al. Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.
[15] P. Giral,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.
[16] Chunhong Bai,et al. Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] K. Cusi,et al. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.
[18] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[19] Brian P. Mulhall,et al. Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.
[20] P. Portincasa,et al. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. , 2012, Clinical biochemistry.
[21] A. Hida,et al. Fatty liver incidence and predictive variables , 2010, Hypertension Research.
[22] L. Matrisian,et al. Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model , 2011, PloS one.
[23] C. Gluud,et al. Hepatic effects of dietary weight loss in morbidly obese subjects. , 1991, Journal of hepatology.
[24] Q. Anstee,et al. Genetics of alcoholic and nonalcoholic fatty liver disease. , 2011, Seminars in liver disease.
[25] D. Freese,et al. A 3-year-old with immunoglobulin G4-associated cholangitis. , 2011, Journal of pediatric gastroenterology and nutrition.
[26] S. Caldwell,et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.
[27] C. Lawton,et al. Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .
[28] S. Piro,et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[29] Yoshiyuki Suzuki,et al. Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma , 2012, The American Journal of Gastroenterology.
[30] T. Berg,et al. High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.
[31] T. Poynard,et al. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious , 2006, Hepatology.
[32] M. Charlton. Nonalcoholic fatty liver disease: a review of current understanding and future impact. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[33] E. Yu,et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. , 2007, Journal of hepatology.
[34] R. Yazdanparast,et al. Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress , 2012, Journal of Biomedical Science.
[35] N. Kawada,et al. Inflammation and fibrogenesis in steatohepatitis , 2012, Journal of Gastroenterology.
[36] F. Mach,et al. Role of cytokines and chemokines in non-alcoholic fatty liver disease. , 2012, World journal of gastroenterology.
[37] S. Caldwell,et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.
[38] M. Arrese,et al. Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass , 2005, Obesity surgery.
[39] A. Suzuki,et al. Chronological development of elevated aminotransferases in a nonalcoholic population , 2005, Hepatology.
[40] S. Grundy,et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.
[41] Giorgio Saracco,et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.
[42] E. Jackvony,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.
[43] H. Sekiguchi,et al. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women , 2010, European Journal of Clinical Nutrition.
[44] J. Gerss,et al. The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. , 2009, Cellular and molecular biology.
[45] Julien Vergniol,et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.
[46] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.
[47] Lisa M Yerian,et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.
[48] Zhou-wen Chen,et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease , 2008, Journal of Zhejiang University SCIENCE B.
[49] D. Aguirre,et al. Fatty liver: imaging patterns and pitfalls. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.
[50] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[51] L. Ferrell,et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease , 2006, Hepatology.
[52] E. Bonora,et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. , 2010, Journal of hepatology.
[53] M. Czaja,et al. Autophagy in nonalcoholic steatohepatitis , 2011, Expert review of gastroenterology & hepatology.
[54] G. Marchesini,et al. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.
[55] W. An,et al. Roles of liver innate immune cells in nonalcoholic fatty liver disease. , 2010, World journal of gastroenterology.
[56] J. Hardies,et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.
[57] Sun Woo Kim,et al. Combined Effect of Nonalcoholic Fatty Liver Disease and Impaired Fasting Glucose on the Development of Type 2 Diabetes , 2011, Diabetes Care.
[58] Yoichiro Kitajima,et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease , 2006, Journal of Gastroenterology.
[59] A. Joseph,et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. , 1991, Clinical radiology.
[60] L. Losi,et al. Nonalcoholic fatty liver disease induced by leuprorelin acetate. , 2008, Journal of clinical gastroenterology.
[61] A. Feldstein,et al. Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease , 2010, Seminars in liver disease.
[62] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[63] R. Loomba,et al. Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis , 2012, Alimentary pharmacology & therapeutics.
[64] D. Schuppan,et al. Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.
[65] P Christoffersen,et al. Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.
[66] Fernando Costa,et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.
[67] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[68] V. Surabhi,et al. Gamut of focal fatty lesions in the liver: imaging manifestations with emphasis on magnetic resonance imaging. , 2010, Current problems in diagnostic radiology.
[69] A. Lonardo,et al. Endocrine and liver interaction: the role of endocrine pathways in NASH , 2009, Nature Reviews Gastroenterology &Hepatology.
[70] T. Barrientos-Gutiérrez,et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. , 2010, The Cochrane database of systematic reviews.
[71] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[72] K. Dewbury,et al. Ultrasound in the detection of chronic liver disease (the "bright liver"). , 1979, The British journal of radiology.
[73] G. Musso,et al. Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism , 2012, Hepatology.
[74] P. Giral,et al. Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.
[75] S. Thung,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Liver Pathology and the Metabolic Syndrome X in , 2022 .
[76] Jae Young Lee,et al. Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging--correlation with histopathologic findings. , 2006, Radiology.
[77] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[78] Joe Kesterson,et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.
[79] Raj Vuppalanchi,et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management , 2009, Hepatology.
[80] G. Gores,et al. Mechanisms of Lipotoxicity in NAFLD and Clinical Implications , 2011, Journal of pediatric gastroenterology and nutrition.
[81] M. Holmqvist,et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.
[82] C. Langlotz,et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. , 1998, AJR. American journal of roentgenology.
[83] M. Uribe,et al. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. , 2010, Annals of hepatology.
[84] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[85] I. Guha,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.
[86] T. Therneau,et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.
[87] Tetsuji Sato,et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. , 2006, Annals of internal medicine.
[88] T. Saibara,et al. Is impaired Kupffer cell function really important to the pathogenesis of nonalcoholic steatohepatitis? , 2012, Journal of Gastroenterology and Hepatology.
[89] M. Karçaaltıncaba,et al. Imaging of hepatic steatosis and fatty sparing. , 2007, European journal of radiology.
[90] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[91] R. Peters,et al. Post-jejunoileal-bypass hepatic disease. Its similarity to alcoholic hepatic disease. , 1975, American journal of clinical pathology.
[92] Mottet Nk,et al. Fatty metamorphosis of the liver associated with jejunoileal bypass. Report of five cases. , 1977 .
[93] Z. Halpern,et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. , 2007, Journal of hepatology.
[94] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[95] C. Palmeira,et al. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free radical biology & medicine.
[96] M. Kremer,et al. Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. , 2008, World journal of gastroenterology.
[97] P. Puvanachandra,et al. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. , 2007, Clinical medicine.
[98] F. Sofi,et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study , 2010, International journal of food sciences and nutrition.
[99] U. Akarca,et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease , 2010, European journal of gastroenterology & hepatology.
[100] Christian Gluud,et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.
[101] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[102] G. Musso,et al. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.
[103] V. Mohan,et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. , 2010, Clinical biochemistry.
[104] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[105] V. de Lédinghen,et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.
[106] N. Chalasani. Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.
[107] A. Sanyal,et al. Pathophysiology guided treatment of nonalcoholic steatohepatitis , 2012, Journal of gastroenterology and hepatology.
[108] G. Gores,et al. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. , 2008, Seminars in liver disease.
[109] A. Feldstein,et al. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications , 2011, Expert review of gastroenterology & hepatology.
[110] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.
[111] B. Neuschwander‐Tetri,et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.
[112] D. Mikhailidis,et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.
[113] S. Haffner,et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. , 2005, Diabetes.
[114] R. Krauss,et al. Diagnosis and management of the metabolic syndrome , 2005 .
[115] E K Outwater,et al. Detection of lipid in abdominal tissues with opposed-phase gradient-echo images at 1.5 T: techniques and diagnostic importance. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.
[116] D. Kleiner,et al. Update on Fatty Liver Disease and Steatohepatitis , 2011, Advances in anatomic pathology.
[117] T. Aoyama,et al. Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis , 2008, Journal of clinical gastroenterology.
[118] Philippe Giral,et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.
[119] D. Flum,et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. , 2003, Archives of surgery.
[120] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[121] K. Kasturi,et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[122] G. Ostapowicz,et al. An association between non‐alcoholic fatty liver disease and polycystic ovarian syndrome , 2009, Journal of gastroenterology and hepatology.
[123] M. Nystrom,et al. MRI steatosis grading: development and initial validation of a color mapping system. , 2012, AJR. American journal of roentgenology.
[124] J. Heimbach,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.
[125] J. Browning. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study , 2006, Hepatology.
[126] L. Burgart,et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.
[127] R. Fisher,et al. Selection and outcome of living donors for adult to adult right lobe transplantation. , 2000, Transplantation.
[128] G. Aithal,et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.
[129] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[130] Vincent Wai-Sun Wong,et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.
[131] D. Berry,et al. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality , 2009, Clinical trials.
[132] M. Pencina,et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? , 2009, Atherosclerosis.
[133] M. Budoff,et al. Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial , 2011, The American Journal of Gastroenterology.
[134] B. Velkeniers,et al. IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS , 2009, Acta clinica Belgica.
[135] F. Schaffner,et al. Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.
[136] N. Chalasani,et al. Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease , 2012, Seminars in Liver Disease.
[137] F. Schmitt,et al. Vitamin E and all-cause mortality: a meta-analysis. , 2011, Current aging science.
[138] E. Shin,et al. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. , 1995, Journal of Korean medical science.
[139] E. Brunt. Non-alcoholic fatty liver disease: what's new under the microscope? , 2011, Gut.
[140] K. Kaita,et al. Fatty Infiltration of Liver in Hyperlipidemic Patients , 2000, Digestive Diseases and Sciences.
[141] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[142] G. Bedogni,et al. Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study , 2006, Alimentary pharmacology & therapeutics.
[143] N. Chalasani,et al. Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes , 2005, The American journal of the medical sciences.
[144] W. Coyle,et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.
[145] Christopher D. Williams,et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.
[146] T. Hamada,et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system , 2010, Journal of hepato-biliary-pancreatic sciences.
[147] D. Amarapurkar,et al. Prevalence of non-alcoholic fatty liver disease: population based study. , 2007, Annals of hepatology.
[148] B. Neuschwander‐Tetri,et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.
[149] M. Waters,et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. , 2011, Endocrinology.